CR20110076A - Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c - Google Patents

Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c

Info

Publication number
CR20110076A
CR20110076A CR20110076A CR20110076A CR20110076A CR 20110076 A CR20110076 A CR 20110076A CR 20110076 A CR20110076 A CR 20110076A CR 20110076 A CR20110076 A CR 20110076A CR 20110076 A CR20110076 A CR 20110076A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
macrociclic
indol
hepatitis
virus
Prior art date
Application number
CR20110076A
Other languages
English (en)
Inventor
Sandrine Marie Helene Vendeville
Pierre Jean-Marie Bernard Raboisson
Tse-I Lin
Abdellah Tahri
Katie Ingrid Eduard Amssoms
Koen Vandyck
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of CR20110076A publication Critical patent/CR20110076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Inhibidores de la replicación del HCV, incluyendo las formas estereoquímicamente isoméricas, y las sales, hidratos y solvatos de dichos inhibidores.
CR20110076A 2008-07-08 2011-02-08 Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c CR20110076A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04

Publications (1)

Publication Number Publication Date
CR20110076A true CR20110076A (es) 2011-11-10

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110076A CR20110076A (es) 2008-07-08 2011-02-08 Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c

Country Status (32)

Country Link
US (2) US8921355B2 (es)
EP (1) EP2310396B1 (es)
JP (2) JP5426671B2 (es)
KR (1) KR101640374B1 (es)
CN (1) CN102089314B (es)
AP (1) AP2743A (es)
AR (1) AR072726A1 (es)
AU (1) AU2009267389B8 (es)
BR (1) BRPI0915887B8 (es)
CA (1) CA2729307C (es)
CL (1) CL2011000032A1 (es)
CO (1) CO6351793A2 (es)
CR (1) CR20110076A (es)
DK (1) DK2310396T3 (es)
EA (1) EA019008B1 (es)
EC (1) ECSP11010750A (es)
ES (1) ES2651038T3 (es)
HK (1) HK1155734A1 (es)
HN (1) HN2011000072A (es)
HR (1) HRP20171892T1 (es)
HU (1) HUE035244T2 (es)
IL (1) IL210086A (es)
LT (1) LT2310396T (es)
MX (1) MX2011000276A (es)
NI (1) NI201100010A (es)
NO (1) NO2310396T3 (es)
NZ (2) NZ590073A (es)
SI (1) SI2310396T1 (es)
SV (1) SV2011003796A (es)
TW (1) TWI454476B (es)
UY (1) UY31973A (es)
WO (1) WO2010003658A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238142T3 (da) 2007-12-24 2012-10-08 Janssen R & D Ireland Makrocykliske indoler som hepatitis C-virusinhibitorer
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
NZ602552A (en) * 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
CN103842330B (zh) 2011-09-02 2016-10-19 诺华股份有限公司 抗炎的取代的环丁烯二酮化合物的胆碱盐
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
EP0902782A1 (en) 1996-04-23 1999-03-24 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CN1196687C (zh) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
KR100891240B1 (ko) 2000-08-30 2009-04-01 파나소닉 주식회사 플라즈마 디스플레이 표시장치 및 그 제조방법
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2620777A1 (en) 2005-09-02 2007-03-08 Tibotec Pharmaceuticals Ltd. Benzodiazepines as hcv inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
AU2007306405A1 (en) 2006-10-10 2008-04-17 Medivir Ab HCV nucleoside inhibitor
AU2007335962B2 (en) * 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
WO2009010785A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
LT2401272T (lt) 2009-02-27 2017-03-27 Janssen Pharmaceuticals, Inc. Hcv makrociklinio slopiklio amorfinė druska
NZ602552A (en) 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
HN2011000072A (es) 2013-09-01
EA019008B1 (ru) 2013-12-30
US9427440B2 (en) 2016-08-30
JP2011527299A (ja) 2011-10-27
SV2011003796A (es) 2011-04-08
CA2729307C (en) 2017-08-29
US20110105473A1 (en) 2011-05-05
HK1155734A1 (en) 2012-05-25
AP2010005521A0 (en) 2010-12-31
IL210086A0 (en) 2011-02-28
CA2729307A1 (en) 2010-01-14
US8921355B2 (en) 2014-12-30
BRPI0915887B8 (pt) 2021-05-25
BRPI0915887B1 (pt) 2020-02-18
JP5426671B2 (ja) 2014-02-26
NI201100010A (es) 2011-09-07
AU2009267389B8 (en) 2013-07-04
SI2310396T1 (en) 2018-01-31
UY31973A (es) 2010-01-29
KR101640374B1 (ko) 2016-07-18
JP2014028818A (ja) 2014-02-13
CN102089314A (zh) 2011-06-08
LT2310396T (lt) 2017-12-27
AP2743A (en) 2013-09-30
AU2009267389A8 (en) 2013-07-04
KR20110040889A (ko) 2011-04-20
BRPI0915887A2 (pt) 2015-11-03
NZ603343A (en) 2013-08-30
CN102089314B (zh) 2014-07-23
IL210086A (en) 2014-05-28
EA201170153A1 (ru) 2011-08-30
TWI454476B (zh) 2014-10-01
WO2010003658A1 (en) 2010-01-14
DK2310396T3 (en) 2017-12-11
JP5808370B2 (ja) 2015-11-10
ES2651038T3 (es) 2018-01-23
AU2009267389A1 (en) 2010-01-14
CO6351793A2 (es) 2011-12-20
HRP20171892T1 (hr) 2018-01-12
EP2310396B1 (en) 2017-09-06
TW201014865A (en) 2010-04-16
NZ590073A (en) 2012-11-30
NO2310396T3 (es) 2018-02-03
EP2310396A1 (en) 2011-04-20
CL2011000032A1 (es) 2011-07-15
MX2011000276A (es) 2011-03-02
ECSP11010750A (es) 2011-08-31
US20140107101A1 (en) 2014-04-17
AR072726A1 (es) 2010-09-15
HUE035244T2 (hu) 2018-05-02
AU2009267389B2 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
CR20110076A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
CY1125436T1 (el) Αναστολεις dna-pk
CY1118111T1 (el) Υποκατεστημενα αλειφανια, κυκλοφανια, ετεραφανια, ετεροφανια, ετερο-ετεραφανια και μεταλλοκενια που ειναι χρησιμα για τη θεραπευτικη αντιμετωπιση hcv λοιμωξεων
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CR10136A (es) Nucleósidos antivirales
AR077765A1 (es) Inhibidores de los virus flaviviridae
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CO6561783A2 (es) Inhibidores del virus flaviviridae
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
DK3436437T3 (da) Substituerede indolinderivativer som dengue¬virus-replikations¬hæmmere
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY34245A (es) Compuestos antivirales para el tratamiento de la hepatitis c (hcv), y métodos de tratamiento.
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
CR20130610A (es) Método de tratamiento de la fiebre dengue
CR20110246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica.